Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2005.01.6071 on October 31 2005

Journal of Clinical Oncology, Vol 23, No 34 (December 1), 2005: pp. 8664-8670
© 2005 American Society of Clinical Oncology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sargent, D. J.
Right arrow Articles by De Gramont, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sargent, D. J.
Right arrow Articles by De Gramont, A.
Related Articles
Right arrowRelated Editorial

Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: Individual Patient Data From 20,898 Patients on 18 Randomized Trials

Daniel J. Sargent, Harry S. Wieand, Daniel G. Haller, Richard Gray, Jacqueline K. Benedetti, Marc Buyse, Roberto Labianca, Jean Francois Seitz, Christopher J. O'Callaghan, Guido Francini, Axel Grothey, Michael O'Connell, Paul J. Catalano, Charles D. Blanke, David Kerr, Erin Green, Norman Wolmark, Thierry Andre, Richard M. Goldberg, Aimery De Gramont

From the North Central Cancer Treatment Group, Mayo Clinic, Rochester, MN; National Surgical Adjuvant Breast and Bowel Project Statistical Center and Operations Office, Pittsburgh; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; QUASAR Collaborative Group, Birmingham and Oxford, United Kingdom; Southwest Oncology Group Statistical Center, Seattle, WA; International Drug Development Institute, Brussels, Belgium; Ospedali Riuniti, Bergamo; University of Siena, Siena, Italy; University of the Mediterranean, Marseilles; Groupe d'Etude et de Recherche Clinique en Oncologie et Radiothérapie, Paris; Hospital Saint Antoine, Paris, France; National Cancer Institute of Canada Clinical Trials Group, Queens University, Kingston, Ontario, Canada; Eastern Cooperative Oncology Group Statistical Center, Boston, MA; Oregon Health and Science University Cancer Institute, Portland, OR; and University of North Carolina, Chapel Hill, NC

Address reprint requests to Daniel Sargent, PhD, Mayo Clinic, 200 First St SW, Rochester, MN 55905; e-mail: sargent.daniel{at}mayo.edu

PURPOSE: A traditional end point for colon adjuvant clinical trials is overall survival (OS), with 5 years demonstrating adequate follow-up. A shorter-term end point providing convincing evidence to allow treatment comparisons could significantly speed the translation of advances into practice.

METHODS: Individual patient data were pooled from 18 randomized phase III colon cancer adjuvant clinical trials. Trials included 43 arms, with a pooled sample size of 20,898 patients. The primary hypothesis was that disease-free survival (DFS), with 3 years of follow-up, is an appropriate primary end point to replace OS with 5 years of follow-up.

RESULTS: The recurrence rates for years 1 through 5 were 12%, 14%, 8%, 5%, and 3%, respectively. Median time from recurrence to death was 12 months. Eighty percent of recurrences were in the first 3 years; 91% of patients with recurrence by 3 years died before 5 years. Correlation between 3-year DFS and 5-year OS was 0.89. Comparing control versus experimental arms within each trial, the correlation between hazard ratios for DFS and OS was 0.92. Within-trial log-rank testing using both DFS and OS provided the same conclusion in 23 (92%) of 25 cases. Formal measures of surrogacy were satisfied.

CONCLUSION: In patients treated on phase III adjuvant colon clinical trials, DFS and OS are highly correlated, both within patients and across trials. These results suggest that DFS after 3 years of median follow-up is an appropriate end point for adjuvant colon cancer clinical trials of fluorouracil-based regimens, although marginally significant DFS improvements may not translate into significant OS benefits.

Supported in part by National Cancer Institute Grant No. CA25224.

Presented in part at the 40th Annual Meeting of the American Society of Clinical Oncology, June 5-8, 2004, New Orleans, LA.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Related Editorial

  • Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: A Commentary
    Judith Abrams
    JCO 2005 23: 8564-8565 [Full Text]


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
I. Zlobec, L. M. Terracciano, and A. Lugli
Local Recurrence in Mismatch Repair-Proficient Colon Cancer Predicted by an Infiltrative Tumor Border and Lack of CD8+ Tumor-Infiltrating Lymphocytes
Clin. Cancer Res., June 15, 2008; 14(12): 3792 - 3797.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
N. L. Keating, M. B. Landrum, C. N. Klabunde, R. H. Fletcher, S. O. Rogers, W. R. Doucette, D. Tisnado, S. Clauser, and K. L. Kahn
Adjuvant Chemotherapy for Stage III Colon Cancer: Do Physicians Agree About the Importance of Patient Age and Comorbidity?
J. Clin. Oncol., May 20, 2008; 26(15): 2532 - 2537.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. O'Connell, M. E. Campbell, R. M. Goldberg, A. Grothey, J.-F. Seitz, J. K. Benedetti, T. Andre, D. G. Haller, and D. J. Sargent
Survival Following Recurrence in Stage II and III Colon Cancer: Findings From the ACCENT Data Set
J. Clin. Oncol., May 10, 2008; 26(14): 2336 - 2341.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Burzykowski, M. Buyse, M. J. Piccart-Gebhart, G. Sledge, J. Carmichael, H.-J. Luck, J. R. Mackey, J.-M. Nabholtz, R. Paridaens, L. Biganzoli, et al.
Evaluation of Tumor Response, Disease Control, Progression-Free Survival, and Time to Progression As Potential Surrogate End Points in Metastatic Breast Cancer
J. Clin. Oncol., April 20, 2008; 26(12): 1987 - 1992.
[Abstract] [Full Text] [PDF]

Home page
 aacredbookHome page
M. E Buyse
Surrogate Endpoints for Efficacy in Clinical Research: Working Definitions and Validation
Am. Assoc. Cancer Res. Educ. Book, April 12, 2008; 2008(1): 659 - 663.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Ng, G. R. Pond, P. A. Tang, P. W. MacIntosh, L. L. Siu, and E. X. Chen
Correlation of changes between 2-year disease-free survival and 5-year overall survival in adjuvant breast cancer trials from 1966 to 2006
Ann. Onc., March 1, 2008; 19(3): 481 - 486.
[Abstract] [Full Text] [PDF]

Home page
 Clin TrialsHome page
B. Goldman, M. LeBlanc, and J. Crowley
Interim futility analysis with intermediate endpoints
Clinical Trials, February 1, 2008; 5(1): 14 - 22.
[Abstract] [PDF]

Home page
 JCOHome page
C. M. Booth and I. Tannock
Reflections on Medical Oncology: 25 Years of Clinical Trials Where Have We Come and Where Are We Going?
J. Clin. Oncol., January 1, 2008; 26(1): 6 - 8.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
S. J. Lim, B. W. Feig, H. Wang, K. K. Hunt, M. A. Rodriguez-Bigas, J. M. Skibber, V. Ellis, K. Cleary, and G. J. Chang
Sentinel Lymph Node Evaluation Does Not Improve Staging Accuracy in Colon Cancer
Ann. Surg. Oncol., January 1, 2008; 15(1): 46 - 51.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Buyse, T. Burzykowski, K. Carroll, S. Michiels, D. J. Sargent, L. L. Miller, G. L. Elfring, J.-P. Pignon, and P. Piedbois
Progression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer
J. Clin. Oncol., November 20, 2007; 25(33): 5218 - 5224.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Grothey
Biological Therapy and Other Novel Therapies in Early-Stage Disease: Are They Appropriate?
Clin. Cancer Res., November 15, 2007; 13(22): 6909s - 6912s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. B. Benson III
New Approaches to Assessing and Treating Early-Stage Colon and Rectal Cancers: Cooperative Group Strategies for Assessing Optimal Approaches in Early-Stage Disease
Clin. Cancer Res., November 15, 2007; 13(22): 6913s - 6920s.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Tang, S. M. Bentzen, E. X. Chen, and L. L. Siu
Surrogate End Points for Median Overall Survival in Metastatic Colorectal Cancer: Literature-Based Analysis From 39 Randomized Controlled Trials of First-Line Chemotherapy
J. Clin. Oncol., October 10, 2007; 25(29): 4562 - 4568.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. J. Sargent, S. Patiyil, G. Yothers, D. G. Haller, R. Gray, J. Benedetti, M. Buyse, R. Labianca, J. F. Seitz, C. J. O'Callaghan, et al.
End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group
J. Clin. Oncol., October 10, 2007; 25(29): 4569 - 4574.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
D. J. Kerr, J. A. Dunn, M. J. Langman, J. L. Smith, R. S.J. Midgley, A. Stanley, J. C. Stokes, P. Julier, C. Iveson, R. Duvvuri, et al.
Rofecoxib and Cardiovascular Adverse Events in Adjuvant Treatment of Colorectal Cancer
N. Engl. J. Med., July 26, 2007; 357(4): 360 - 369.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. J. A. Punt, M. Buyse, C.-H. Kohne, P. Hohenberger, R. Labianca, H. J. Schmoll, L. Pahlman, A. Sobrero, and J.-Y. Douillard
Endpoints in Adjuvant Treatment Trials: A Systematic Review of the Literature in Colon Cancer and Proposed Definitions for Future Trials
J Natl Cancer Inst, July 4, 2007; 99(13): 998 - 1003.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
J.-T. Liang, K.-C. Huang, H.-S. Lai, P.-H. Lee, and C.-T. Sun
Oncologic Results of Laparoscopic D3 Lymphadenectomy for Male Sigmoid and Upper Rectal Cancer with Clinically Positive Lymph Nodes
Ann. Surg. Oncol., July 1, 2007; 14(7): 1980 - 1990.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. P. Kuebler, H. S. Wieand, M. J. O'Connell, R. E. Smith, L. H. Colangelo, G. Yothers, N. J. Petrelli, M. P. Findlay, T. E. Seay, J. N. Atkins, et al.
Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07
J. Clin. Oncol., June 1, 2007; 25(16): 2198 - 2204.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. B. Benson III
The Hope for Today--The Promise for Tomorrow: Will Oncologists Meet the Challenge?
J. Clin. Oncol., June 1, 2007; 25(16): 2156 - 2158.
[Full Text] [PDF]

Home page
 JCOHome page
H. B. Muss, L. Biganzoli, D. J. Sargent, and M. Aapro
Adjuvant Therapy in the Elderly: Making the Right Decision
J. Clin. Oncol., May 10, 2007; 25(14): 1870 - 1875.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
B. M. Wolpin, J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer
Adjuvant Treatment of Colorectal Cancer
CA Cancer J Clin, May 1, 2007; 57(3): 168 - 185.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
Transatlantic Laparoscopically Assisted vs Open Co
Laparoscopically Assisted vs Open Colectomy for Colon Cancer: A Meta-analysis
Arch Surg, March 1, 2007; 142(3): 298 - 303.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
A. B. Benson III
Adjuvant Therapy for Pancreatic Cancer: One Small Step Forward
JAMA, January 17, 2007; 297(3): 311 - 313.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
J.-T. Liang, K.-C. Huang, H.-S. Lai, P.-H. Lee, and Y.-M. Jeng
Oncologic Results of Laparoscopic Versus Conventional Open Surgery for Stage II or III Left-Sided Colon Cancers: A Randomized Controlled Trial
Ann. Surg. Oncol., January 1, 2007; 14(1): 109 - 117.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
K. V. Ballman, J. C. Buckner, P. D. Brown, C. Giannini, P. J. Flynn, B. R. LaPlant, and K. A. Jaeckle
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
Neuro-oncol, January 1, 2007; 9(1): 29 - 38.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Portier, D. Elias, O. Bouche, P. Rougier, J.-F. Bosset, J. Saric, J. Belghiti, P. Piedbois, R. Guimbaud, B. Nordlinger, et al.
Multicenter Randomized Trial of Adjuvant Fluorouracil and Folinic Acid Compared With Surgery Alone After Resection of Colorectal Liver Metastases: FFCD ACHBTH AURC 9002 Trial
J. Clin. Oncol., November 1, 2006; 24(31): 4976 - 4982.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. M. van Geelen, J. L. Westra, E. G. de Vries, W. Boersma-van Ek, N. Zwart, H. Hollema, H. M. Boezen, N. H. Mulder, J. T. Plukker, S. de Jong, et al.
Prognostic Significance of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand and Its Receptors in Adjuvantly Treated Stage III Colon Cancer Patients
J. Clin. Oncol., November 1, 2006; 24(31): 4998 - 5004.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Pfisterer, M. Plante, I. Vergote, A. du Bois, H. Hirte, A. J. Lacave, U. Wagner, A. Stahle, G. Stuart, R. Kimmig, et al.
Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG
J. Clin. Oncol., October 10, 2006; 24(29): 4699 - 4707.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
D. L. Bartlett, J. Berlin, G. Y. Lauwers, W. A. Messersmith, N. J. Petrelli, and A. P. Venook
Chemotherapy and Regional Therapy of Hepatic Colorectal Metastases: Expert Consensus Statement
Ann. Surg. Oncol., October 1, 2006; 13(10): 1284 - 1292.
[Full Text] [PDF]

Home page
 Ann OncolHome page
I Chau and D Cunningham
Adjuvant therapy in colon cancer--what, when and how?
Ann. Onc., September 1, 2006; 17(9): 1347 - 1359.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Glynne-Jones, S. Mawdsley, T. Pearce, and M. Buyse
Alternative clinical end points in rectal cancer--are we getting closer?
Ann. Onc., August 1, 2006; 17(8): 1239 - 1248.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Gill and D. Sargent
End points for adjuvant therapy trials: has the time come to accept disease-free survival as a surrogate end point for overall survival?
Oncologist, June 1, 2006; 11(6): 624 - 629.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
T. Akasu, Y. Moriya, Y. Ohashi, S. Yoshida, K. Shirao, S. Kodaira, and for the National Surgical Adjuvant Study of Colore
Adjuvant Chemotherapy with Uracil-Tegafur for Pathological Stage III Rectal Cancer after Mesorectal Excision with Selective Lateral Pelvic Lymphadenectomy: A Multicenter Randomized Controlled Trial
Jpn. J. Clin. Oncol., April 1, 2006; 36(4): 237 - 244.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Abrams
Disease-Free Survival Versus Overall Survival As a Primary End Point for Adjuvant Colon Cancer Studies: A Commentary
J. Clin. Oncol., December 1, 2005; 23(34): 8564 - 8565.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online